L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350)

Antiviral Research

Volumn 39, Issue 2, 1998, Pages 101-111

  Robinson Jr , W Edward ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Antiviral agents; Experimental therapeutics; Reverse transcriptase

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CICHORIC ACID; INTEGRASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PRIORITY JOURNAL; REVIEW;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0344061520     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00037-0     Document Type: Article

References (73)

1. Aboulker J., Swart A.M. Preliminary analysis of the Concorde trial. Lancet. 1:1993;889-890.
2. Abrams, D., Cotton, D., Markowitz, M., Mayer, M., 1996. AR-177 (Zintevir). In: AIDS/HIV Treatment Directory, vol. 8. AmFAR, New York, pp. 50-51.
3. Alteri E., Bold G., Cozens R., Faessler A., Klimkait T., Lang M., Lazdins J., Poncioni B., Roesel J.L., Schneider P. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob. Agents Chemother. 37:1993;2087-2092.
4. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., Katlama C., Debre P., Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116.
5. Baldwin E.T., Bhat T.N., Liu B., Pattabiraman N., Erickson J.W. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat. Struct. Biol. 2:1995;244-249.
6. Billich A., Schauer M., Frank S., Rosenwirth B., Billich S. HIV integrase: high-level production and screening assay for the endonucleolytic activity. Antiviral Chem. Chemother. 3:1992;113-119.
7. Bowerman B., Brown P.O., Bishop J.M., Varmus H.E. A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev. 3:1989;469-478.
8. Brinkworth R.I., Fairlie D.P. Non-peptidic anti-AIDS agents: inhibition of HIV-1 proteinase by disulfonates. Biochem. Biophys. Res. Commun. 188:1992;624-630.
9. Brinkworth R.I., Woon T.C., Fairlie D.P. Inhibition of HIV-1 proteinase by non-peptide carboxylates. Biochem. Biophys. Res. Commun. 176:1991;241-246.
10. Bukrinsky M.I., Sharova N., McDonald T.L., Pushkarskaya T., Tarpley W.G., Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc. Natl. Acad. Sci. USA. 90(13):1993;6125-6129.
11. Burke T.R., Fesen M.R., Mazumder A., Wang J., Carothers A.M., Grunberger D., Driscoll J., Kohn K., Pommier Y. Hydroxylated aromatic inhibitors of HIV-1 integrase. J. Med. Chem. 38:1995;4171-4178.
12. Caliendo A.M., Hirsch M.S. Combination therapy for infection due to human immunodeficiency virus type 1. Clin. Infect. Dis. 18:1994;516-524.
13. Cannon P.M., Wilson W., Byles E., Kingsman S.M., Kingsman A.J. Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues. J. Virol. 68:1994;4768-4775.
14. Carteau S., Mouscadet J.F., Goulaouic H., Subra F., Auclair C. Inhibitory effect of the polyanionic drug suramin on the in vitro HIV DNA integration reaction. Arch. Biochem. Biophys. 305:1993;606-610.
15. Carteau S., Mouscadet J.F., Goulaouic H., Subra F., Auclair C. Inhibition of the in vitro integration of Moloney murine leukemia virus DNA by the DNA minor groove binder netropsin. Biochem. Pharmacol. 47:1994;1821-1826.
16. Cherepanov P., Este J.A., Rando R.F., Ojwang J.O., Reekmans G., Steinfeld R., David G., DeClercq E., Debyser Z. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol. Pharmacol. 52:1997;771-780.
17. Clumeck N. Current use of anti-HIV drugs in AIDS. J. Antimicrob. Chemother. 32(Suppl. A):1993;133-138.
18. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V.J., Friedman H.M., Merigan T.C., Reichman R.C., Hooper C., Corey L. Treatment of human immunodeficiency virus infection with saquinavir, Zidovudine, and zalcitabine. New Engl. J. Med. 334:1996;1011-1017.
19. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Titus D., Yang T., Teppler H., Squires K.E., Deutsch P.J., Emini E.A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571.
20. Connor R.I., Mohri H., Cao Y., Ho D.D. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency type 1-infected individuals. J. Virol. 67:1993;1772-1777.
21. European-Australian Collaborative Group, Cooper D.A. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. New Engl. J. Med. 329:1993;297-303.
22. Craig J.C., Duncan I.B., Hockley D., Grief C., Roberts N.A., Mills J.S. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res. 16:1991;295-305.
23. Culberson J.C., Bush B.L., Sardana V.V. Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis. Methods Enzymol. 241:1994;385-394.
24. Cushman M., Sherman P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions. Biochem. Biophys. Res. Commun. 185:1992;85-90.
25. Cushman M., Golebiewski W.M., Pommier Y., Mazumder A., Reymen D., De Clercq E., Graham L., Rice W.G. Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase. J. Med. Chem. 38:1995;443-452.
26. Deminie C.A., Bechtold C.M., Stock D., Alam M., Djang F., Balch A.H., Chou T.-C., Prichard M., Colonno R.J., Lin P.-F. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob. Agents Chemother. 40:1996;1346-1351.
27. Farnet C., Wang B., Lipford J.R., Bushman F.D. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc. Natl. Acad. Sci. USA. 93:1996;9742-9747.
28. Fesen M.R., Kohn K.W., Leteurtre F., Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc. Natl. Acad. Sci. USA. A 90:1993;2399-2403.
29. Fesen M.R., Pommier Y., Leteurtre F., Hiroguchi S., Yung J., Kohn K.W. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 48:1994;595-608.
30. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., Chodakewitz J.A. Treatment with indinavir, Zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl. J. Med. 337:1997;734-739.
31. Gulnik S.V., Suvorov L.I., Liu B., Yu B., Anderson B., Mitsuya H., Erickson J.W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry. 34:1995;9282-9287.
32. AIDS Clinical Trials Group, Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron J.J., Feinberg J.E., Balfour H.H. Jr., Deyton L.R., Chodakewitz J.A., Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New Engl J Med. 337:1997;725-733.
33. Heinzinger N.K., Burkinsky M.I., Haggerty S.A., Ragland A.M., Kewalramani V., Lee M.-A., Gendelman H., Ratner L., Stevenson M., Emerman M. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl. Acad. Sci. USA. 91:1994;7311-7315.
34. Hirsch M.S. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. J. Infect. Dis. 161:1990;845-857.
35. Ho D.D., Toyoshima T., Mo H., Kempf D.J., Norbeck D., Chen C.M., Wideburg N.E., Burt S.K., Erickson J.W., Singh M.K. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:1994;2016-2020.
36. Hong H., Neamati N., Wang S., Nicklaus M.C., Mazumder A., Zhao H., Burke T.R. Jr., Pommier Y., Milne G.W.A. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 40:1997;930-936.
37. Johnson V.A., Merrill D.P., Chou T.C., Hirsch M.S. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and Zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-alpha A against Zidovudine-sensitive or -resistant HIV-1 in vitro. J. Infect. Dis. 166:1992;1143-1146.
38. 2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob. Agents Chemother. 36:1992;926-933.
39. Kline M.W., Fletcher C.V., Federici M.E., Harris A.T., Evans K.D., Rutkiewicz V.L., Shearer W.T., Dunkle L.M. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics. 97:1996;886-890.
40. Kulkosky J., Jones K.S., Katz R.A., Mack J.P.G., Skalka A.M. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol. Cell. Biol. 12:1992;2331-2338.
41. LaFemina R.L., Schneider C.L., Robbins H.L., Callahan P.L., LeGrow K., Roth E., Schleif W.A., Emini E.A. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 66:1992;7414-7419.
42. LaFemina R.L., Graham P.L., LeGrow K., Hastings J.C., Wolfe A., Young S.D., Emini E.A., Hazuda D.J. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob. Agents Chemother. 39:1995;320-324.
43. Larder B.A., Darby G., Richman D.D. HIV with reduced sensitivity to Zidovudine (AZT) isolated during prolonged therapy. Science. 243:1989;1731-1734.
44. Larder B.A., Kemp S.D., Harrigan P.R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 269:1995;696-699.
45. Maschera B., Furfine E., Blair E.D. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69:1995;5431-5436.
46. Mazumder A., Cooney D., Agbaria R., Gupta M., Pommier Y. Inhibition of human immunodeficiency virus type 1 integrase by 3′-azido-3′-deoxythymidylate. Proc. Natl. Acad. Sci. USA. 91:1994;5771-5775.
47. Mazumder A., Neamati N., Sommadossi J.-P., Gosselin G., Schinazi R.F., Imbach J.-L., Pommier Y. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase. Mol. Pharmacol. 49:1996;621-628.
48. 3. Scand. J. Immunol. 45:1997;103-111.
49. McDougall B., King P.J., Wu B.W., Hostomsky Z., Reinecke M.G., Robinson W.E. Jr. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob. Agents Chemother. 42:1998;140-146.
50. Montefiori D.C., Robinson W.E. Jr., Schuffman S.S., Mitchell W.M. Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:1988;231-235.
51. Munroe J.E., Hornback W.J., Campbell J.B., Ouellette M.A., Hatch S.D., Muesing M.A., Wiskerchen M.A., Baxter A.J., Su K., Campanale K. LY316340: a potent HIV-1 protease inhibitor containing a high affinity octahydrothienopyridine hydroxyethylamine isostere. Bioorg. Med. Chem. Lett. 5:1995;2885-2890.
52. Neamati N., Hong H., Mazumder A., Wang S., Sunder S., Nicklaus M.C., Milne G.W.A., Proksa B., Pommier Y. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J. Med. Chem. 40:1997;942-951.
53. Nicklaus M.C., Neamati N., Hong H., Mazumder A., Sunder S., Chen J., Milne G.W.A., Pommier Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 40:1997;920-929.
54. Ojwang J.O., Buckheit R.W., Pommier Y., Mazumder A., deVreese K., Este J.A., Reymen D., Pallansch L.A., Lackman-Smith C., Wallace T.L., deClercq E., McGrath M.S., Rando R.F. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:1995;2426-2435.
55. Otto M.J., Garber S., Winslow D.L., Reid C.D., Aldrich P., Jadhav P.K., Patterson C.E., Hodge C.N., Cheng Y.S. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc. Natl. Acad. Sci. USA. 90:1993;7543-7547.
56. Partaledis J.A., Yamaguchi K., Tisdale M., Blair E.E., Falcione C., Maschera B., Myers R.E., Pazhanisamy S., Futer O., Cullinan A.B. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:1995;5228-5235.
57. Patick A.K., Boritzki T.J., Bloom L.A. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 41:1997;2159-2164.
58. Poiesz B.J., Ruscetti F.W., Gazder A.F., Bunn B.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA. 77:1980;7415-7419.
59. Pollard R.B. Use of proteinase inhibitors in clinical practice. Pharmacotherapy. 14:1994;21S-29S.
60. Robinson W.E. Jr., Montefiori D.C., Gillespie D.H., Mitchell W.M. Complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro increases HIV-1 RNA and protein synthesis and infectious virus production. J. Acquired Immune Defic. Syndr. 2:1989;33-42.
61. Robinson W.E. Jr., Cordeiro M., Abdel-Malek S., Jia Q., Chow S.A., Reinecke M.G., Mitchell W.M. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus (HIV) integrase: inhibition of the core catalytic domain of HIV integrase. Mol. Pharmacol. 50:1996;846-855.
62. Robinson W.E. Jr., Reinecke M.G., Abdel-Malek S., Jia Q., Chow S.A. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. USA. 93:1996;6326-6331.
63. Roe T.Y., Reynolds T.C., Yu G., Brown P.O. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12:1993;2099-2108.
64. Rooke R., Parniak M.A., Tremblay M., Soudeyns H., Li X., Gao Q., Yao X.-J., Wainberg M.A. Biological comparison of wild-type and Zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob. Agents Chemother. 35:1991;988-991.
65. Stevenson M., Stanwick T.L., Dempsey M.P., Lamonica C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9:1990;1551-1560.
66. Swanstrom R. Characterization of HIV-1 protease mutants: random, directed, selected. Curr. Opin. Biotechnol. 5:1994;409-413.
67. Taddeo B., Haseltine W.A., Farnet C.M. Integrase mutants of human immunodeficiency virus type 1 with a specific defect in integration. J. Virol. 68:1994;8401-8405.
68. Tisdale M., Myers R.E., Maschera B., Parry N.R., Oliver N.M., Blair E.D. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1995;1704-1710.
69. Turriziani O., Antonelli G., Jacobsen H., Mous J., Riva E., Pistello M., Dianzani F. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol. 38:1994;297-298.
70. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases, Volberding P.A. Zidovudine in asymptomatic human immunodeficiency virus infection. New Engl. J. Med. 322:1990;941-949.
71. Zhao H., Neamati N., Hong H., Mazumder A., Wang S., Sunder S., Milne G.W.A., Pommier Y., Burke T.R. Jr. Coumarin-based inhibitors of HIV integrase. J. Med. Chem. 40:1997;242-249.
72. Zhao H., Neamati N., Mazumder A., Sunder S., Pommier Y., Burke T.R. Jr. Arylamide inhibitors of HIV-1 integrase. J. Med. Chem. 40:1997;1186-1194.
73. Zhao H., Neamati N., Sunder S., Hong H., Wang S., Milne G.W.A., Pommier Y., Burke T.R. Jr. Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem. 40:1997;937-941.